» Articles » PMID: 20851648

Histamine in the Regulation of Wakefulness

Overview
Journal Sleep Med Rev
Date 2010 Sep 21
PMID 20851648
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

The histaminergic system is exclusively localized within the posterior hypothalamus with projection to almost all the major regions of the central nervous system. Strong and consistent evidence exist to suggest that histamine, acting via H₁ and/or H₃ receptor has a pivotal role in the regulation of sleep-wakefulness. Administration of histamine or H₁ receptor agonists induces wakefulness, whereas administration of H₁ receptor antagonists promotes sleep. The H₃ receptor functions as an auto-receptor and regulates the synthesis and release of histamine. Activation of H₃ receptor reduces histamine release and promotes sleep. Conversely, blockade of H₃ receptor promotes wakefulness. Histamine release in the hypothalamus and other target regions is highest during wakefulness. The histaminergic neurons display maximal activity during the state of high vigilance, and cease their activity during non-rapid eye movement (NREM) and rapid eye movement (REM) sleep. The cerebrospinal levels of histamine are reduced in diseased states where hypersomnolence is a major symptom. The histamine deficient L-histidine decarboxylase knockout (HDC KO) mice display sleep fragmentation and increased REM sleep during the light period along with profound wakefulness deficit at dark onset, and in novel environment. Similar results have been obtained when histamine neurons are lesioned. These studies strongly implicate the histaminergic neurons of the TMN to play a critical role in the maintenance of high vigilance state during wakefulness.

Citing Articles

HDC downregulation induced by chronic stress promotes ovarian cancer progression via the IL-6/STAT3/S100A9 pathway.

Chen Z, Cao J, Xiao Z, Yang Z, Cheng Y, Duan J Front Pharmacol. 2024; 15:1485885.

PMID: 39720595 PMC: 11666360. DOI: 10.3389/fphar.2024.1485885.


Abnormal hypothalamic functional connectivity and serum arousal-promoting neurotransmitters in insomnia disorder patients: a pilot study.

Lin J, Luo Z, Fan M, Liu Y, Shi X, Cai Y PeerJ. 2024; 12:e18540.

PMID: 39583108 PMC: 11586044. DOI: 10.7717/peerj.18540.


The Utility of Betahistine Dihydrochloride, a Structural Analog of Histamine, in Clozapine-associated Daytime Sedation: A Case Series.

Agarwal S, Charan D, Kumar R, Pardal P Indian J Psychol Med. 2024; :02537176241226902.

PMID: 39564225 PMC: 11572314. DOI: 10.1177/02537176241226902.


Prevalence of Diamine Oxidase Enzyme (DAO) Deficiency in Subjects with Insomnia-Related Symptoms.

Lopez Garcia R, Ferrer-Garcia J, Sansalvador A, Quera-Salva M J Clin Med. 2024; 13(16).

PMID: 39200725 PMC: 11354289. DOI: 10.3390/jcm13164583.


Microstructural changes in the inferior tuberal hypothalamus correlate with daytime sleepiness in Lewy body disease.

Cohen J, Radhakrishnan H, Olm C, Das S, Cook P, Wolk D medRxiv. 2024; .

PMID: 39185524 PMC: 11343243. DOI: 10.1101/2024.08.16.24312102.


References
1.
Dauvilliers Y, Arnulf I, Mignot E . Narcolepsy with cataplexy. Lancet. 2007; 369(9560):499-511. DOI: 10.1016/S0140-6736(07)60237-2. View

2.
Lakoski J, Gallager D, Aghajanian G . Histamine-induced depression of serotoninergic dorsal raphe neurons: antagonism by cimetidine, a reevaluation. Eur J Pharmacol. 1984; 103(1-2):153-6. DOI: 10.1016/0014-2999(84)90202-4. View

3.
Khateb A, Muhlethaler M, Alonso A, Serafin M, Mainville L, Jones B . Cholinergic nucleus basalis neurons display the capacity for rhythmic bursting activity mediated by low-threshold calcium spikes. Neuroscience. 1992; 51(3):489-94. DOI: 10.1016/0306-4522(92)90289-e. View

4.
Monti J, Pellejero T, Jantos H . Effects of H1- and H2-histamine receptor agonists and antagonists on sleep and wakefulness in the rat. J Neural Transm. 1986; 66(1):1-11. DOI: 10.1007/BF01262953. View

5.
Aston-Jones G . Brain structures and receptors involved in alertness. Sleep Med. 2005; 6 Suppl 1:S3-7. DOI: 10.1016/s1389-9457(05)80002-4. View